Evidence map›Paper›PMID 39596207›Full record

ArticleInternational journal of molecular sciences2024

SOCS1 Inhibits IL-6-Induced CD155 Overexpression in Lung Adenocarcinoma.

Mario Marroquin-Muciño, Jesus J Benito-Lopez, Mario Perez-Medina, Dolores Aguilar-Cazares, Miriam Galicia-Velasco, Rodolfo Chavez-Dominguez, Sergio E Meza-Toledo, Manuel Meneses-Flores, Angel Camarena, Jose S Lopez-Gonzalez

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mario Marroquin-MuciñoLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.ORCID 0009-0000-7557-2343
Jesus J Benito-LopezLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.ORCID 0009-0004-1660-0550
Mario Perez-MedinaLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.ORCID 0000-0002-9308-2521
Dolores Aguilar-CazaresLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.
Miriam Galicia-VelascoLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.
Rodolfo Chavez-DominguezLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.ORCID 0000-0002-4097-6011
Sergio E Meza-ToledoLaboratorio de Quimioterapia Experimental, Departamento de Bioquimica, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0003-0447-7642
Manuel Meneses-FloresLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.
Angel CamarenaLaboratorio de Inmunobiologia y Genetica, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.
Jose S Lopez-GonzalezLaboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.ORCID 0000-0003-0746-2286

Funding

Consejo Nacional de Ciencia y Tecnologia 284775
6 · The paper itself

Abstract

CD155, also known as the poliovirus receptor (PVR), is a crucial molecule in the development and progression of cancer, as its overexpression favors immune evasion and resistance to immunotherapy. However, little is known about the mechanisms that regulate its overexpression. Proinflammatory factors produced by various cellular components of the tumor microenvironment (TME) have been associated with CD155 expression. We analyzed the effect of interleukin (IL)-6 on CD155 expression in lung adenocarcinoma. We found a positive relationship between mRNA and protein levels. This correlation was also observed in bioinformatics analysis and in biopsies and serum from patients with lung adenocarcinoma. Interestingly, lung adenocarcinoma cell lines expressing suppressor of cytokine signaling 1 (SOCS1) did not show increased CD155 levels upon IL-6 stimulation, and SOCS1 silencing reverted this effect. IL-6 and SOCS1 are critical regulators of CD155 expression in lung adenocarcinoma. Further basic and clinical studies are needed to define the role of these molecules during tumor development and to improve their clinical impact as biomarkers and targets for predicting the efficacy of immunotherapies. This study deepens the understanding of the intricate regulation of the immune checkpoints mediated by soluble factors and allows us to devise new ways to combine conventional treatments with the most innovative anticancer options.

Indexed as

Adenocarcinoma of LungGene Expression Regulation, NeoplasticInterleukin-6Lung NeoplasmsReceptors, VirusSuppressor of Cytokine Signaling 1 ProteinCell Line, TumorHumansTumor MicroenvironmentIL6 protein, humanInterleukin-6poliovirus receptorReceptors, VirusSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinIL-6 CD155immunotherapylung adenocarcinomaPVRSOCS1

Identifiers

PMID39596207
PMCPMC11595078

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.